Examining the effects of furosemide on toxin levels in chronic kidney disease patients
The Effect of Furosemide on Protein-Bound Uremic Toxin Plasma Levels and Excretion in Patients with Chronic Kidney Disease
This study is testing whether the diuretic furosemide affects the levels of certain toxins in the blood and urine of people with chronic kidney disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 34 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | UMC Utrecht Academic / other |
| Locations | 1 site (Utrecht, Utrecht) |
| Trial ID | NCT06750575 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how the diuretic furosemide affects the plasma levels and urinary excretion of protein-bound uremic toxins (PBUTs) in patients with chronic kidney disease (CKD). Participants will be monitored before and after starting furosemide treatment, with blood and urine samples collected to assess changes in PBUT levels. The study aims to clarify whether furosemide increases PBUT levels by reducing their renal excretion, which could have implications for patient health. The design includes invasive measurements and a prospective repeated measures approach.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with CKD stage 3-5 and an indication for furosemide treatment.
Not a fit: Patients already on furosemide, those with liver disease, or those requiring renal replacement therapy will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of toxin levels in CKD patients, potentially reducing morbidity and mortality.
How similar studies have performed: While the interaction between furosemide and PBUTs is not extensively studied, similar approaches in managing CKD have shown promise, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * An age of 18 years or older * An eGFR \<60 mL/min/1.73m2 for at least three months (diagnosis of CKD stage 3-5) * An indication for the start of treatment with furosemide as part of routine patient care * Willingness to participate in the study and a signed informed consent Exclusion Criteria: * Patients who are already on furosemide treatment * Patients with a liver disease with hyperbilirubinemia * Patients who receive any type of renal replacement therapy (peritoneal dialysis, haemodialysis) * Patients with end-stage renal failure without residual diuresis * Patients who will start with medication simultaneously with start of furosemide treatment that might interfere with PBUT excretion or PBUT protein binding * Patients who are incapacitated
Where this trial is running
Utrecht, Utrecht
- University Medical Center Utrecht (UMCU) — Utrecht, Utrecht, Netherlands (Recruiting)
Study contacts
- Principal investigator: Karin GF Gerritsen, MD, PhD — UMC Utrecht
- Study coordinator: Dian P Bolhuis, MD, MSc
- Email: d.p.bolhuis-3@umcutrecht.nl
- Phone: +31-887557375
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.